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Abstract 
 Melarsoprol (Mel B) is the only efficacious drug against late stage Human African Trypanosomiasis 
(HAT), but inadvertently is very toxic and induces Post Treatment Reactive Encephalopathy (PTRE) that is 
lethal in 5% of the patients. Investigations were conducted to establish the neuro-protective role of Coenzyme 
Q10 (CoQ10) and other cellular antioxidants ((Manganese Superoxide dismutase (MnSOD), Glutathione 
Reductase (GR), Copper-Zinc Superoxide dismutase (SOD-1) and glutathione (GSH)) against Mel B toxicity, 
PTRE and putative resultant brain degeneration in a mouse model. Female Swiss-white mice were infected with 
Trypanasoma brucei rhodesiense parasite and manipulated to simulate all phases of PTRE and HAT. Expression 
profiles of the antioxidants in brain tissues were assessed using immunoblots, while GSH was measured 
spectrophotometrically. Trypanosoma brucei rhodesiense infection resulted in elevation of expression of 
endogenous antioxidants in the early stage of infection (21dpi), with significant expression (two fold) observed 
at the terminal stage of the disease (57dpi). CoQ10 assisted in boosting Levels of GSH upon induction of severe 
late stage of HAT. Similarly CoQ10 administration significantly augmented levels of SOD-1, GR and GSH in 
infected than in uninfected mice that were treated with Melarsoprol. The time dependent dynamics of antioxidant 
suppression due to Melarsoprol, and potential ameliorating effects of CoQ10 on the same, indicate putative 
mechanism underlying and antidote to the toxicity of the drug with potential application in formulation of novel 
Melarsoprol-based drugs and development of novel markers for staging the disease. 
Key Words: Trypanasoma brucei rhodesiense, endogenous antioxidants, late stage HAT; Coenzyme Q10; 
Melarsoprol;  
 
Abbreviations: GSH, glutathione; CoQ10, Coenzyme Q10; MnSOD, Manganese Superoxide dismutase; GR, 
Glutathione Reductase; SOD-1, Copper-Zinc Superoxide dismutase; Mel B, melarsoprol; PTRE, Post treatment 
reactive encephalopathy; HAT, Human African Trypanoomiasis; HEPES, N-2 hydroxyethylpiperazine-N`-2 
ethane sulfonic acid; ICDH, isocitrate dehydrogenase; LDH, lactate dehydrogenase; MnSOD, manganese 
superoxide dismutase; NADP
+
, nicotinamide adenine dinucleotide phosphate, NO, nitric oxide; ONOO
-, 
peroxynitrite; ROS, reactive oxygen species; SDS, sodium dodecyl sulfate; TCA, tricarboxylic acid; DAB, 
diaminobenzidine;  PBS, Phosphate buffered saline; dpi, days post infection. 
 
1. INTRODUCTION 
 Human African Trypanosomiasis (HAT), or sleeping sickness, a neglected tropical disease that occurs 
in sub-Saharan Africa, is caused by Trypanosoma brucei gambiense or Trypanosoma brucei rhodesiense 
parasite. The disease is classified into early and late stages.The late stage is accompanied by neurological 
dysfunction due to invasion of the brain by the parasites (Kennedy, 2004). HAT due to T. b. rhodesiense causes 
acute infection with CNS invasion occurring 21 days post infection (dpi) (Fevre et al. 2005). The invasion is 
associated with chronic meningitis that progresses to encephalitis and neuronal degeneration (Penetreath, 1995). 
Immunological factors accompanying the HAT progression have been well documented (Lejon et al. 2001). 
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However, the impact of the infection on antioxidant system is poorly understood despite established roles of 
endogenous antioxidants in ameliorating deleterious effects of pathogenic infections (Rubbo et al. 1994). The 
trivalent organic arsenical melarsoprol is the only effective drug for late-stage disease in both forms of HAT 
since the drug crosses the blood-brain barrier. However, the drug is potentially toxic to humans, resulting in 
mortality of up to 5% of the patients treated, due to post treatment reactive encephalopathy (PTRE) (Pepin and 
Milrod, 1994). Molecular processes that mediate the PTRE are poorly understood, and yet the process holds the 
key to counteracting the deleterious effects of PTRE and resultant mortality of patients. It is notable that despite 
efforts to develop newer drugs for CNS stage HAT, a drug as toxic as melarsoprol is still the only effective 
treatment for the late stage rhodesience infections. It is therefore prudent to dedicate resources to conduct 
research on strategies that would alleviate its toxicity and safe lives. 
 Hypotheses advanced to date suggest that PTRE is a product of toxicity of the arsenical moiety of 
melarsoprol (Hunter et al. 1992; Soignet et al. 1999). The toxicity is elicited by melarsen oxide, a metabolite of 
melarsoprol, which binds to vital metabolic enzymes resulting in oxidative stress (Fairlamb et al. 2003; 
Halliwell, 2001). The oxidative stress causes cellular damage and subsequently neurodegeneration. This is 
attributable to oxidation of vital cellular components by reactive oxygen species (ROS) and induction of nitric 
oxide synthase (iNOS) and synthesis of nitric oxide (NO) metabolites (Gorman et al. 1996; Keita et al. 2000). 
The NO facilitates generation of lethal reactive metabolite species such as peroxynitrite (ONOO
-
) in the brain, 
which nitrate vital proteins and/or enzymes in the brain, altering their structure and rendering them 
dysfunctional (Keita et al. 2000).  
 The brain counteracts the resultant oxidative stress through superoxide dismutase (SOD), glutathione 
peroxidase (GPX), catalase (CAT) and glutathione (GSH) antioxidant defense systems that scavenge the 
radicals (Mataix et al. 1998). However, the ROS and NO metabolites can deplete the antioxidant defenses 
(Bolanos et al. 1995; Heals and Bolanos, 2002), increasing susceptibility of the neurons to oxidative stress, 
which in turn impairs their functions with putative resultant neurological dysfunction. Brain degeneration 
outcome in HAT is therefore partially a product of antioxidant factor suppression and resultant oxidative stress.    
Coenzyme Q10 is a powerful antioxidant that is known to cross the blood brain barrier (Matthews et al. 
1998). This has generated interest in the potential usefulness of CoQ10 to treat neurodegenerative diseases such 
as Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (Meredith et al. 2009). 
Importantly, CoQ10 protect against β -amyloid toxicity (McCarthy, 2004; Winkler-Stuck et al. 2004) and has 
been observed to effectively attenuate toxicity in transgenic mice following administration with 3-Nitropropionic 
acid (Matthews et al. 1998). In cultured cerebellar neurons, CoQ10 provide protection against glutamate toxicity 
(Favit et al. 1992). However, the potential role of CoQ10 in concert with endogenous antioxidant systems in 
protection or amelioration of Mel B toxicity to humans remains to be determined.  
This study was initiated to establish responses of neuronal endogenous antioxidant systems (MnSOD, 
SOD-1, GSH and GR) in a mouse model to Mel B and/or infection by T. b. rhodesiense in the absence or 
presence of Mel B and /or CoQ10. Our data indicates that endo- or exogenous elevation of the antioxidant factors 
such as infusion of CoQ10 might potentially ameliorate the brain damage and concomitant clinical manifestations 
as a result of Mel B toxicity or T. b. rhodesiense parasites.  
 
2. MATERIALS AND METHODS 
2.1 Ethics Statement 
 This study was undertaken in adherence to experimental guidelines and procedures approved by the 
Institutional Animal Care and Use Committee (IACUC), the ethical review committee for the use of laboratory 
animals. A standard protocol was drawn up in accordance with the Good Laboratory Practice (GLP) regulation 
of the KARI-TRC. 
2.2 Experimental Animals, Parasites and drugs 
A colony of 60 eight-weeks-old female adult Swiss-white mice (20-30g) was obtained from Kabete 
Veterinary Investigation Laboratories in Nairobi, Kenya. The mice were maintained on mice pellets (Unga Feeds 
Ltd, Kenya) and water ad libitum at room temperature. Wood-chippings were provided as bedding material. All 
mice were treated with 0.02ml of invermectin (Ivermectin®, Anupco, Suffolk, England) injected subcutaneously 
to each mouse to rid the mice of ecto and endo parasites. The mice were allowed to acclimatize for two weeks 
before they were subjected to experimental procedures. Trypanosoma brucei rhodesiense parasites were sourced 
as cryo-preserved clone KETRI 2537 from  Kenya Agricultural Reserach Institute- Trypanosomiasis Research 
Center (KARI-TRC), Muguga, Kenya). The parasite strain was previously isolated from a human host in Uganda 
in 1972. Melarsoprol (Special Paris Rsobal) was provided by WHO and  Veriben® was acquired from Ceva 
Sante Animale La b Allastere 33501 Libourne Cedex , France. 
2.3 Experimental design  
The experiments were conducted in ten groups each consisting of six mice (Table 1).  Mice in the first 
group served as healthy controls (un-infected).  The second and third groups were infected with T. b. rhodesiense 
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for 21 and 57 days respectively. Mice in the sixth group were also infected with T. b. rhodesiense for 21 days 
and subsequently treated for four days with Mel B while those in the seventh group were similarly treated but 
had orally been treated with CoQ10 on every other day from seven days prior to infection by the parasite up to the 
termination of the group four (healthy controls/un-infected) experiments. Mice in the fifth group (uninfected 
mice) were treated in a similar manner to those in the sixth group but were uninfected. The fourth group were 
uninfected mice controls for the fifth, sixth and seventh groups. Mice in the eighth group were infected as the 
fourth group but treated with Diaminazine aceturate (to induce PTRE) (5mg/kg/day) instead of Mel B 21dpi for 
three days to induce/simulate PTRE. The mice were subsequently treated with Mel B when relapse of the 
infection was observed. Mice in group 9 were treated in a similar manner to those in group 8 but had orally been 
treated with CoQ10 on every other day from seven days prior to infection with the parasite up to the termination 
of the experiment. The relapse in group eight and nine occurred at 19-32 days while those in group 9 occurred at 
30-44 dpi. The last group consisted of uninfected mice, and served as a control for groups eight and nine. Mel B 
and CoQ10 were administered at 3.6 mg/kg/day and 200mg/kg respectively. All mice in each group were 
euthanized with chloroform (trichloromethane) at the end of respective experimental setting. 
 
Table1. Experimental groups and drug treatments 
Mice group  Number of mice Treatment 
Group 1   6    Uninfected (control) 
Group 2  6   T. b. rhodesiense–infected (sacrificed 21dpi)  
Group 3   6    T. b. rhodesiense–infected (terminal end) 
Group 4  6   Uninfected (control) 
Group 5   6    Uninfected treated with Mel B 
Group 6   6    T. b. rhodesiense–infected treated with Mel B treated 
Group 7   6    T. b. rhodesiense–infected, CoQ10 treated with Mel B 
Group 8   6   T. b. rhodesiense–infected PTRE induced and Mel B 
Group 9  6   T. b. rhodesiense–infected, CoQ10, PTRE induced and 
     Mel B treated 
Group 10   6    uninfected (control) 
Key: dpi-days post infection, Mel B – melarsoprol, CoQ10 – Coenzyme Q10, PTRE – Post treatment reactive 
encephalopathy. 
2.4 Harvesting and processing of brain samples for analyses 
The brain samples were harvested separately (21dpi, 25days after last dosage of Mel B, 57dpi and 65 
days) from each of the euthanized and immediately washed in PBS at 4
0
C. The brains were then snap frozen on 
dry ice in labeled cryotubes, before finally being stored in liquid nitrogen. The snap-frozen whole brains were 
homogenized on ice water (4oC) in 0.5 ml of homogenization buffer (0.25 M sucrose, 5 mM Hepes-Tris, pH 7.4, 
protease inhibitor cocktail (Sigma Aldrich) to make 10% (w/v) brain homogenate. The brain homogenates were 
later used for various biochemical analyses.  
2.5 Assessment of GSH, MnSOD, SOD-1 and GR in the brain samples  
 The levels of GSH among the aliquots of the brain samples were separately determined 
spectrophotometrically (in relation to the time brain sample were harvested) based on Ellman’s reagent 
(DTNB) using a multi-detection microplate reader (Bio-Tek Synergy HT). The expression profiles of 
MnSOD (SOD2), Cu/ZnSOD (SOD1) and GR were determined using Western blotting (SDS-PAGE).  
Proteins were separated on cast gradient gels (4–15% Tris–HCl, SDS Polyacrylamide) at 125 constant volts 
using the BioRad systems. After electrophoresis, the proteins were transferred and bound to a nitrocellulose 
membrane (Millipore) at 25 V for 150 min. Once the transfer was complete, the membranes were incubated 
in 5-10 (w/v) fat-free milk (blocking solution) for 4 hours at room temperature. The blocking solution was 
then discarded and the blots incubated in solutions containing, primary monoclonal antibodies (Santa Cruz 
Biotechnology, Santa Cruz CA) for MnSOD1, MnSOD2, and GR, respectively followed by their respective 
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peroxidase-conjugated secondary antibodies. The protein-antibody complexes were then visualized with the 
development system containing 0.10% 3, 3’-diaminobenzidine (DAB) in PBS (pH 7.4) containing 100 µl of 
30% hydrogen peroxide.  The relative levels of SOD-1, SOD-2 and GR were then determined using pixel 
density software UN-SCAN-IT (NIH, MD,). β-actin was used to confirm equal sample loading for all gel 
electrophoresis. All studies were carried out at least in triplicate 
2.6 Statistical analyses 
The statistical analysis was carried out using one-way ANOVA and post-hoc Bonferronis’ test for 
multiple comparisons with significance level set at P<0.05. The statistical analyses was done using GraphPad 
Prism version 5 Software Inc., (San Diego, CA). 
3. RESULTS 
3.1 Effects of T. b. rhodesiense infection, PTRE induction, Mel B and CoQ10 on synthesis of GSH in brain 
Endogenous levels of glutathione were significantly higher (P = 0.0034) in T. b. rhodesiense infected 
mice sacrificed 21dpi than in control mice. Progression of the infection to the terminal stage beyond 21dpi 
reduced GSH levels (Fig.1a.). Treatment with Mel B depleted GSH in uninfected mice. Infected mice treated 
with Mel B had significantly lower (P = 0.0001) GSH levels than in those infected but orally administered with 
CoQ10 and treated with Mel B (Fig.1b.). Glutathione levels were significantly (P<0.05) higher in infected PTRE 
induced mice (Mel B treated) than in control mice. In infected PTRE mice treated with Mel B, levels of GSH 
were significantly higher ((P = 0.0017) than in respective infected mice (PTRE induced) that were given CoQ10 
and treated with Mel B (Fig.1c).  
 
Figure 1 (a). Mean reduced glutathione (GSH) concentration in brain homogenates of uninfected (control), T. 
b. rhodesiense infected mice sacrificed 21dpi and T. b. rhodesiense infected sacrificed at terminal stage 
(57dpi). (b). Mean GSH concentration in brain homogenates of control, uninfected treated with Mel B, T. b. 
rhodesiense infected mice treated with Mel B and T. b. rhodesiense infected orally administered with CoQ10 
and treated with Mel B. (c). Mean GSH concentration in brain homogenates of uninfected (control), T. b. 
rhodesiense infected mice PTRE induced Mel B treated and T. b. rhodesiense infected orally administered with 
CoQ10 PTRE induced Mel B treated.  
3.2 Effect of T. b. rhodesiense, Mel B, PTRE and CoQ10 on the expression of Glutathione reductase 
 Results of the expression of glutathione reductase (GR) in PTRE-induced Mel B and CoQ10 treated in 
infected mice are presented in Fig. 2 a, b, c. Statistical analyses revealed significantly higher GR expression in T. 
b. rhodesiense infected mice brain homogenates sacrificed 21dpi relative to the control mice (P=0.0001). On the 
other hand, GR expression was significantly elevated in brain homogenates of mice that were at the terminal 
stage than those at 21dpi (Fig.2b.)  (P= 0.0006).Treatment with Mel B significantly lowered GR expression in 
uninfected mice relative to the control mice (P= 0.0001) (Fig.2a.).  Infection of mice with T. b. rhodesiense and 
treatment with Mel B resulted in significantly higher expression of GR than in control mice (P=0.0001) (Fig.2a.). 
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Similarly, in infected mice treated with CoQ10 and Mel B, GR expression was significantly higher relative to the 
control mice (P=0.0001). The expression of GR in uninfected mice treated with Mel B was significantly lower 
relative to the T. b. rhodesiense infected mice treated with Mel B (P=0.0001). Similarly, Bonferroni's post hoc 
test comparison of the means revealed significantly higher expression of GR in brain homogenates of infected 
mice (PTRE induced) treated with Mel B than in control mice  (P=0.0006).  Infected mice in which PTRE had 
been induced and which were  administered with  CoQ10 and Mel B, GR expression was significantly lower 
relative to infected mice (PTRE induced) treated with Mel B, without CoQ10 (Fig.2c.). 
 
Figure 2 (a). (A) Blot showing differences in the expression of Glutathione reductase protein in brain 
homogenate fractions from: (a) control, (b) uninfected mice treated with Mel B, (c) T. b. rhodesiense infected 
mice treated with Mel B 21dpi sacrificed 24hrs after the last dosage and (d) T. b. rhodesiense infected mice 
orally administered with 200mg/kg CoQ10 treated with Mel B 21dpi. A p value (P<0.05) is considered significant 
for comparative studies. (B) The histogram shows semi-quantitative determinations of GR protein expression, 
presented as percentage pixel intensity. (b). Determination of GR expression; (A) Immuno-blot of nitrocellulose 
membranes showing specific expression of GR protein that was determined in (a) uninfected (control), (b) 
infected sacrificed 21dpi and (c) infected terminal stage brain homogenate. (c). Determination of GR expression; 
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(A) The blot shows specific expression of GR protein  which was determined in (a) uninfected (control), (b) 
infected PTRE induced and Mel B treated and (c) infected orally administered with CoQ10 PTRE induced and 
Mel B treated brain homogenate. β-actin was used to show equal loading. (B)The histogram shows semi-
quantitative determinations of GR protein expression, presented as percentage pixel intensity.  
3.3 Effect of Mel B, PTRE induction, CoQ10 treatment and Trypanasoma brucei rhodesiense on SOD-1 
expression at different stages of HAT 
Results of the expression of SOD-1 in infected mice in which PTRE was induced and were 
administered with Mel B and CoQ10 are presented in Fig. 3a, b, c.  The expression levels of SOD-1 in infected 
mice sacrificed 21dpi (P=0.0001) were higher than in the control mice;, with the expression of SOD-1 being 
significantly  (P=0.0001) elevated at the terminal stage of T .b. rhodesiense infection than infected mice 
sacrificed 21dpi (Fig.3a.). When challenged with T .b. rhodesiense infection and upon treatment with Mel B, the 
brain homogenates of these mice showed a significant (P=0.0001) increase in expression of SOD-1 than control 
mice (Fig.3b.). Similarly, Bonferroni's post hoc test comparison of the means revealed significantly higher 
expression of SOD-1 in T. b. rhodesiense infected mice (PTRE induced orally administered with CoQ10) treated 
with Mel B relative to the control mice (Fig.3c.). 
 
Figure 3 (a). Increased expression of SOD-1 in T. b. rhodesiense infected brain homogenates. (A) Blot showing 
specific expression of SOD-1 which was determined in: (a) uninfected (control) (b) infected sacrificed 21dpi and 
(c) infected terminal stage brain homogenate. (B) The histogram shows semi-quantitative determinations of GR 
protein expression, presented as percentage pixel intensity. (b). Increased expression of SOD-1 in T. b. 
rhodesiense infected brain homogenates of T. b. rhodesiense infected PTRE induced and Mel B treated. (A) Blot 
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showing specific expression of SOD-1 which was determined in: (a) uninfected (control), (b) infected orally 
administered with CoQ10, PTRE induced and Mel B treated and (c) infected PTRE induced and Mel B treated 
following relapse brain homogenate. (B) The histogram shows semi-quantitative determinations of GR .protein 
expression, presented as percentage pixel intensity. (c). Increased expression of SOD-1 in T. b. rhodesiense 
infected brain homogenates of T. b. rhodesiense infected treated with Mel B. (A) Blots showing specific 
expression of SOD-1 which was  determined in: (a) uninfected (control), (b) uninfected treated with Mel B, 
infected orally administered with CoQ10 treated with Mel B and (c) infected treated with Mel B brain 
homogenate. (B) The histogram shows semi-quantitative determinations of SOD-1 protein expression, presented 
as percentage pixel intensity. 
3.4 Effect of T. b. rhodesiense infection, PTRE, Mel B and CoQ10 treatment on the expression of MnSOD 
in mice brain homogenates 
 Results of the expression of MnSOD in PTRE-induced Mel B and CoQ10 treated mice (infected) are 
presented in Fig. 4a,b,c. Statistical analyses indicated   significant differences in expression levels of MnSOD in 
T .b. rhodesiense infected mice at terminal stages  (P=0.0004); much higher than mice sacrificed 21dpi. 
Expression of MnSOD in T .b. rhodesiense infected mice sacrificed at 21dpi was significantly higher (P=0.0004) 
than in control mice (Fig.4a.). Similarly, Bonferroni's post hoc test comparison of the means revealed 
significantly lower expression of MnSOD in uninfected Mel B treated mice relative to the control mice  
(P=0.0004). On the other hand, in infected mice treated with CoQ10 and Mel B showed a significantly higher 
expression of MnSOD than in infected Mel B treated  (P=0.0004) (Fig.4b.) mice. Similarly, expression of 
MnSOD in brain homogenates of T. b. rhodesiense infected mice (PTRE induced) treated with Mel B was 
significantly (P=0.0004) lower than those administered with CoQ10. T .b. rhodesiense infected mice (PTRE 
induced, Mel B treated) showed significantly (P=0.0004) lower expression of MnSOD than in control mice 
(Fig.4c.). 
 
Figure 4 (a). Semi-Quantitative determinations of MnSOD; (A) Blot showing MnSOD protein expression in: (a) 
control, (b) T. b. rhodesiense infected sacrificed 21dpi and (c) T. b. rhodesiense infected terminal stage. 
(B) The histogram shows semi-quantitative determinations of GR protein expression, presented as percentage 
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pixel intensity. (b). Semi-Quantitative determinations of MnSOD; (A) Blot showing MnSOD protein expression 
in: (a) uninfected (control), (b) uninfected treated with Mel B, (c) infected orally administered with CoQ10 
treated with Mel B and (d) infected treated with Mel B brain.  (B)The histogram shows semi-quantitative 
determinations of MnSOD protein expression, presented as percentage pixel intensity. (c). Semi-Quantitative 
determinations of MnSOD, (A) Blot showing MnSOD protein expression in: (a) control, (b) infected orally 
administered with CoQ10 PTRE induced and Mel B treated and (c) infected PTRE induced and Mel B treated 
following relapse brain homogenates, which is expressed as percentage pixel.  
 
4. DISCUSSION 
 Our results show that invasion of the brain by T. b rhodesiense induces elevation of GSH levels, while 
Mel B and progression of the infection to terminal stage significantly depletes GSH. The levels of brain GSH at 
21dpi tends to be elevated than those in the corresponding control and infected mice that went to the terminal 
end; suggesting a vital role of the cellular antioxidant system in the pathogenesis of HAT. Such a role creates 
an opportunity and target for scientists to explore as they strife to identify new targets for drug development or 
other interventions to improve treatment outcomes in HAT. Establishment of T. b. rhodesiense in CNS by 
21dpi normally results in production of free radicals, which in turn stimulates total GSH to combat the 
deleterious effects of ROS. As the infection progress towards the terminal end, oxidative stress tends to 
overwhelm the antioxidant system as demonstrated by the low levels of GSH. Given the robust antioxidant role 
played by GSH in the brain, its depletion would make neurons and other cells in the brain vulnerable. This 
observation is in agreement with other studies in which cellular GSH content was depleted as a result of 
elevated oxidative stress (Dukhande et al. 2006). Similarly, GSH recycling is impaired due to NADPH and 
isocitrate dehydrogenase inactivation as a result of generation of ROS (Dukhande et al. 2006). In another study, 
increased levels of free radicals depleted GSH in chronic schizophrenia (Gora et al. 2006). Similarly, 
significant depletion of GSH was depicted in kidney, blood and liver in experimental infection of T. congolense 
(umar et al. 2010). In fact, the trypanosome parasite antioxidant trypanothione is synthesized from its 
mammalian equivalent, glutathione (Smith et al. 1992). This phenomenon implies that the trypanosomes 
protect themselves from oxidative stress at the expense of the mammalian host; and could deplete GSH needed 
to protect the human brain, resulting in oxidative stress. This scenario appears to suggest that with further 
investigations, coupling of anti-oxidant therapy with conventional treatment regimens might improve treatment 
outcome in HAT. 
 Reactive oxygen species can play an important role in health; however, overproduction of the same 
can do great damage in the brain and even result in neurodegeneration. Activation of astrcocytes due to parasite 
invasion of the brain is accompanied by nitric oxide (NO) production. Though beneficial, it has been postulated 
that NO can potentially harm brain cells due to overproduction. Specifically, NO facilitates generation of lethal 
reactive metabolite species such as peroxynitrite (ONOO-) (Heals and Balanos, 2002) in the brain, which nitrate 
vital proteins and/or enzymes, altering their structure and rendering them dysfunctional. Moreover, the 
metabolites depletes cellular antioxidant defenses such as glutathione (GSH) and superoxide dismutases (SOD) 
(Bolanos et al. 1997), increasing susceptibility of the  neurons to oxidative stress, which in turn impairs their 
functions with putative resultant neurological dysfunction generally observed in the late stages of HAT 
infections.  
Furthermore, our study clearly showed that treatment of uninfected mice with Mel B resulted in 
glutathione depletion in the brain. It is possible that melarsen oxide, a toxic metabolite of Mel B impairs critical 
proteins/enzymes necessary for GSH restoration in the CNS. Mel B is arsenic-based drug. Arsenic has the ability 
to complex with sulphydryl groups depleting cellular reduced glutathione (GSH) levels also GSH depletion is 
strongly promoted by arsenic-induced apoptosis and enhanced arsenic-induced ROS formation (Del-Razo et al. 
2001; Davison et al. 2003).  
Oral administration of CoQ10 in infected mice that were treated with Mel B resulted in increased levels 
of GSH. Such a profound finding indicates that CoQ10 can support GSH status in the brain during Mel B 
treatment and reduce mortality due to Mel B toxicity. Hence these findings provide some evidence for a potential 
treatment regime for HAT incorporating CoQ10.  Note that previous studies have reported that depletion of 
endogenous GSH antioxidant may be a significant factor in the pathogenesis of T. congolense infection. In this 
study, administration of exogenous vitamin C to infected animals, prevented disease-induced decreases in GSH 
and ascorbic acid (Umar et al. 2010). This assumption is supported by the fact that Coenzyme Q10 has been 
reported to effectively attenuate toxicity in transgenic mice following administration with 3-Nitropropionic acid 
(Matthews et al. 1998); and protection against glutamate toxicity in cultured cerebral neurons ( Favit et al. 
1992). Despite obvious shortcomings in our data in explaining the mechanistic details of cellular amount of 
Coenzyme Q10 penetrated and concentrated in the CNS, we propose that oral administration of CoQ10 could be 
used to block GSH depletion due Mel B toxicity and could attenuate PTRE. Additionally, we suggest that CoQ10 
could be useful in maintenance of endogenous antioxidants in the brain during HAT therapy. 
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Note that oral administration of 200mg/kg of CoQ10 in infected mice in which PTRE had been induced 
at 21dpi and treated with Mel B following relapse resulted in elevated GSH. Moreover, in un-supplemented 
mice, the induction of GSH was more marked. Results from this study suggest that an increase in GSH, to a 
certain extent could alleviate the effect of oxidative stress induced by PTRE and virulent effect of T. b. 
rhodesiense, by boosting antioxidant activity. 
Since treatment with DA induces PTRE and clears the parasite from the haemolymphatic system and 
not the CNS, it is plausible that both PTRE and parasites in the CNS could be the major contributing factors of 
ROS that led to the increase in levels of GSH. Following relapse and treatment with Mel B, the GSH levels 
decreased than the expected values due to Mel B toxicity. The observed low levels of GSH in the CoQ10 orally 
administered, PTRE induced and Mel B treated mice could be attributed to the antioxidant capability of CoQ10 
not only to attenuate the toxicity of Mel B, but also to provide protection against generated oxidative stress. 
Consistent with this possibility, is an earlier observation that in vitro supplementation with CoQ10 provided DNA 
protection against hydrogen peroxide induced oxidative stress (Tomasetti et al. 1999). Clearly further studies are 
required to test this intriguing possibility in primates. 
Our results further show a robust antioxidant enzyme response from MnSOD, Cu/ZnSOD and GR in the 
initial stages of infection (mice sacrificed 21dpi) with T. b. rhodesiense to the terminal end. The notion that by 
21dpi the parasite have established within the CNS is well documented, thus by this period the impairment of 
major components of the CNS was on course. This includes components of the electron transport chain and 
oxidative phosphorylation which enhances an increased free radical leakage and thereby inducing oxidative 
stress, and subsequently stimulating MnSOD, SOD-1 and GR expression and activity. The expressions of these 
important proteins that constitute the first line of defense for ROS removal were markedly increased as the 
infection progress towards the terminal end.  
Robust overexpression of MnSOD, Cu/ZnSOD-1 and GR demonstrates there protective role in brain 
cells threatened with T. b. rhodesiense infection or oxidative stress. In an earlier observation in cells challenged 
with energy failure by mitochondrial toxins and/or oxidative stress, there was induction of MnSOD and NADP
+
-
ICDH activity. Consequently, the observed progression of infection towards terminal stage in CNS resulting into 
elevated oxidative stress was accompanied by acute increase in MnSOD, SOD-1 and GR protein expression in 
our study. This suggests that the three proteins act in concert and are critical in the control of oxidative stress. 
The implication is that presence of ROS brought about by T. b. rhodesiense infection may exert stimulatory or 
inductive effect on MnSOD, SOD-1 and GR expression. 
It was noted that the level of expression of MnSOD and GR decreased in uninfected mice treated with 
Mel B. These findings clearly demonstrate the toxic effect of Mel B that resulted in depletion of MnSOD and 
GR. Melarsen oxide, a metabolite of melarsoprol has been shown to interact with thiols such as glutathione and 
thioredoxin forming a stable adduct (Fairlamb et al. 1989; Cunningham et al. 1994). The stable adduct formed is 
a competitive inhibitor of the respective flavoproteins namely glutathione reductase and thioredoxin reductase, 
whose responsibility is to maintain intracellular thioredoxin and glutathione in the reduced form (Cunningham et 
al. 1994). Melarsen oxide also potently inhibits the flavoproteins glutathione reductase and thioredoxin reductase 
directly by interacting with catalytically active sulphydryl groups present in both enzymes. Other studies reveal 
that in addition to causing mitochondrial toxicity (Larochette et al. 1999) impairing microtubule polymerization, 
(Li and Broome, 1999) and deregulating a number of proteins and enzymes through sulfhydryl binding, 
(Cavigelli et al. 1996), the arsenic induces oxidative stress and generation of hydrogen peroxide and other ROS 
(Wang et el. 1996). Mel B depletion of MnSOD in this study should not be a surprise because the mitochondrion 
is known to accumulate arsenic (Mazumder, 2005). This is an indication that possibly, Mel B toxicity targets 
vital mitochondrial processes in the brain. Other studies have shown evidence that arsenic molecules suppress 
MnSOD (Mazumder, 2005). 
Once in the mitochondria, the arsenic is known to inhibit succinic dehydrogenase activity and can 
uncouple oxidative phosphorylation. The resulting fall in ATP levels affects a number of cellular functions 
including expression of MnSOD protein synthesis.  Consistent with this observation is an in vitro study that was 
done to determine the effect of arsenical compounds on GSH-related enzymes glutathione-reductase, peroxidase 
and transferase (Chouchane and Snow, 2001). In this study, arsenic appeared to be an effective inhibitor of all of 
the proteins studied (Thomas et al. 2001). In light of this, MnSOD and GR depletion may be an important 
mechanism underlying Mel B induced neurotoxicity.  
Additionally, treatment of infected mice with Mel B also showed depletion of MnSOD. As early noted 
during progression of infection, there is elevation of MnSOD. Thus it can be conclusively argued that before 
treatment, expression of MnSOD is induced by ROS; triggered by T. b. rhodesiense infection, but treatment with 
Mel B impairs expression of MnSOD, perhaps due to Melarsoprol toxicity and PTRE.  
CoQ10  has  been  studied  in  multiple  in  vitro  models  of neuronal  toxicity,  with  results  that  
overall  have  supported a  neuroprotective  effect. In  neuronal  cell  models  of  oxidative  stress,  pre-treatment  
with  CoQ10  preserves  mitochondrial membrane  potential  and  reduces  generation  of  reactive oxygen species 
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(Somayajulu et al. 2005). Since T. b. rhodesiense is known to cause acute infection, production of ROS as a 
result of this parasite is extremely robust thus expression of MnSOD was important despite administration of 
CoQ10. Consequently this study shows that CoQ10 can aid in quenching ROS. Apart from neutralizing the toxic 
effect of Mel B, exogenous CoQ10 can also can play an integral role in maintaining endogenous CoQ10 levels.   
Importantly, CoQ10 has been shown to protect human neuroblastoma  (SHSY-5Y)  cells  against  
paraquat-induced mitochondrial  dysfunction  as  well  as  against β -amyloid  toxicity (Winkler-Stuck et al. 
2004). Thus, these findings suggest that other factors are required for the targeting of CoQ10 to the mitochondria 
and sub-cellular distribution in order to enhance its maximal antioxidant protective effect against MnSOD 
depletion either by oxidative stress or Mel B toxicity. However, in the current study, SOD-1 was highly 
expressed in the mice on CoQ10 compared to the control and infected mice on Mel B alone. Supplementation 
with CoQ10 has a profound effect on protecting SOD-1 against oxidative stress and toxic effects of Mel B and 
PTRE. It is noteworthy that increased levels of malondialdehyde and down-regulation of SOD-1, both markers 
of oxidative stress observed in the transgenic mice, were ameliorated by CoQ10 treatment (Young et al. 2008). 
Similarly, in a transgenic mouse model of familial ALS that overexpresses SOD-1 with the G93 A mutation, 
treatment with CoQ10 at 200 mg/kg/day, significantly increased mean life span Matthews et al. 1998). Moreover, 
the current studies pinpoint putative crucial events that may precede or supersede depletion of the antioxidants 
by Mel B and elevation of oxidative stress that could trigger neurodegeneration. Some of the crucial events like 
oral administration of CoQ10 may be “protective’’ in nature. Consequently, there is need to understand how 
CoQ10 interacts with Mel B to ameliorate its toxicity. 
Glutathione reductase protein normally acts to maintain high levels of reduced glutathione in the 
cytosol, with the concomitant oxidation of NADPH. GR transforms oxidized glutathione to the reduced form, 
thus elevation of this important protein in both CoQ10 infected mice on Mel B and infected mice on Mel B 
(without CoQ10) indicate the important role it plays during oxidative stress.  
The rise in expression of SOD-1 and GR protein activity during severe late stage was similar to the 
increase observed for both of them and MnSOD during initial stages of infection and at the terminal stage. There 
was an increased expression of GR in infected, PTRE induced and Mel B treated mice compared to the control. 
Note that treatment with diaminazine aceturate induces PTRE (Pepin, 1994). PTRE may be a major factor for 
increased production of ROS other than that induced by the parasites. Hence presence of PTRE and parasites can 
lead to a rise in SOD-1 and GR, when compared to CoQ10 supplemented mice. This study noted an increase in 
the expression of SOD-1 in CoQ10 orally administered, PTRE induced and Mel B treated mice suggesting that 
CoQ10 and SOD-1 act in concert in protecting brain cells against harmful effect of ROS. This is another 
indication that CoQ10 could alleviate PTRE and Mel B toxicity. Expression of both SOD-1 and GR is vital for 
maintenances of a robust antioxidant system that is functional. Other studies have revealed that overexpression 
of MnSOD and GPx protects neurons from the harmful effects of ROS in experimental stroke (Wallace, 2002; 
Hoen et al. 2004).  
Normally brain cells have very high energy requirements and therefore exhibit a high rate of ROS 
production from the mitochondrial electron transport activities coupled to oxidative phosphorylation (Hinerfeld 
et al. 2004). In light of the finding of a significant decrease in expression of MnSOD in PTRE mice treated with 
Mel B at relapse when compared to PTRE mice that received CoQ10 and Mel B, it possible that PTRE induction 
increased oxidative stress leading to depletion and inactivation of this important antioxidant. Peroxynitrite 
(ONOO
-
) has been shown to inactivate MnSOD, GPx and GR expression
 
(Macmillan-Crow et al. 1996; Savvides 
et al. 2002) and cellular GSH content is generally depleted as a result of induction of oxidative stress (Dukhande 
et al. 2006). Understanding the role of vital antioxidant systems during active PTRE as a result of Mel B toxicity 
and oxidative stress as a result of T. b. rhodesiense infection, could be important for development of 
pharmacological and/or nutritional strategies to counter oxidative stress in the brain challenged with T. b. 
rhodesiense infection.  
Previous studies (Jo et al. 2002; Munich et al. 2003) and the findings from this study demonstrate the 
important role MnSOD, SOD-1, GSH and GR in combating oxidative stress in brain challenged with T. b. 
rhodesiense. The observed depletion of GSH in the terminal stage prompts to speculate that T. b. rhodesiense 
infection of the brain results into neurological dysfunction, which may impair NADPH generation and 
subsequently deplete intracellular GSH or its synthesis and intercellular cycling (Lee et al. 2003). 
 
5. CONCLUSION 
In conclusion, this study provides new information on how the brain challenged with T. b. rhodesiense 
infection, treatment with Mel B and oral administration of CoQ10 alters the antioxidant system. Our results 
suggest that antioxidant system regulated by MnSOD, SOD-1, GR and GSH protects brain cells during HAT 
disease process and from Mel B toxicity. The time-dependent dynamics of antioxidant suppression due to Mel B, 
and potential ameliorating effects of CoQ10 on the same, indicate putative mechanisms with potential application 
in formulation of novel Mel B-based drugs that would be less toxic and safer to use. 
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